This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy

This study has been completed.
Information provided by (Responsible Party):
China Medical University Hospital Identifier:
First received: May 30, 2012
Last updated: March 11, 2015
Last verified: March 2015
This is a randomized, double-blind, placebo-controlled, 2-period crossover, 12-week trial to be conducted in 50 subjects with painful diabetic neuropathy. The objective of this trial is to assess the safety and efficacy of NO gel, a NO donor, as compared with a placebo gel, in symptom relief of subjects with painful diabetic neuropathy.

Condition Intervention Phase
Neuropathic Pain Drug: nitric oxide gel Drug: placebo gel Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy

Resource links provided by NLM:

Further study details as provided by China Medical University Hospital:

Primary Outcome Measures:
  • Neuopathic Pain Scale [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • vascular duplex parameters [ Time Frame: 12 weeks ]
  • the likelihood of reusing the nitric oxide gel recorded [ Time Frame: 12weeks ]

Enrollment: 24
Study Start Date: July 2012
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: nitric oxide gel
  1. st gel: sodium nitrites
  2. nd gel: maleic/ascorbic acids
Drug: nitric oxide gel
  1. st gel: sodium nitrites,BID local use X 28 days
  2. nd gel: maleic/ascorbic acids ,BID local use X 28 days
Placebo Comparator: Placebo gel
  1. st gel: phosphate-buffered saline
  2. nd gel: maleic/ascorbic acids
Drug: placebo gel
placebo gel,BID local use X 28 days

Detailed Description:
Neuropathic pain is a common symptom of diabetic neuropathy, and predominantly involves the lower limbs. Current strategies for the management of painful diabetic neuropathy include improved glycemic control, use of analgesics and addition of tricyclic antidepressants and anticonvulsants. However, many patients experience unsatisfactory responses and some undesired side effects. Considerable evidence implicates impaired nitric oxide synthesis plays an important role in the pathogenesis of diabetic neuropathic pain. Several small studies have shown that topical nitroglycerin ointment has local vasodilating properties, and a previous study has demonstrated that isosorbide dinitrate in spray form as a nitric oxide donor relieved some neuropathic symptoms in patients with painful diabetic neuropathy. Based on the findings, the investigators hypothesize that nitric oxide gel could be used as an alternative pain-relieving agent for patients with resistant diabetic neuropathic pain.

Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects>=30 and<=80 years of age.
  2. Subjects with type 1 or type 2 diabetes mellitus with painful diabetic neuropathy.
  3. Subjects without undergoing treatment for painful diabetic neuropathy or with treatment for at least 3 months but still presenting neuropathic pain prior to randomization.
  4. Subjects who are healthy without any serious diseases that require hospitalization during the study period.
  5. Subjects who are capable of understanding and having signed the Informed Consent Form after detailed description of the treatment procedures and potential risks and benefits.

Exclusion Criteria:

  1. Subjects with diagnosis of cancer and are still on active therapies.
  2. Subjects with diagnosis of an active disease (e.g. hyper-or-hypothyroidism, advanced chronic renal failure, severe anemia, liver cirrhosis, active infectious disease etc.) and are still under regular treatment for this disease
  3. Subjects with peripheral neuropathy caused by a known acute or chronic disease or injury
  4. Subjects who are on other medications with pharmacological actions that may lead to excessive formation of nitric oxide (e.g. sublingual nitroglycerin, sildanafil etc.) or may accentuate drug effects due to excessive formation of nitric oxide.
  5. Subjects with severe peripheral artery disease leading to absence of foot pulses.
  6. Subjects with erratic glycemic control (HbA1c 12).
  7. Subjects with an active foot ulceration or infection.
  8. Subjects with any known allergic reaction to any ingredient in the 2 gel preparations.
  9. Subjects who have been enrolled into any clinical study in the preceding 3 months prior to randomization.
  10. Subjects with current substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of the study result
  11. Female subject of childbearing potential who is lactating or has positive urine pregnancy test at V0 or refuses to adop reliable method of contraception during the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01633086

China Medical University Hospital
Taichung, Taiwan, 404
Sponsors and Collaborators
China Medical University Hospital
Principal Investigator: Ching-Chu Chen, M.D. China Medical University Hospital
Study Director: Ching-Chu Chen, M.D China Medical University Hospital
  More Information

Responsible Party: China Medical University Hospital Identifier: NCT01633086     History of Changes
Other Study ID Numbers: DMR99-IRB-273
Study First Received: May 30, 2012
Last Updated: March 11, 2015

Additional relevant MeSH terms:
Diabetic Neuropathies
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Nitric Oxide
Ascorbic Acid
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Protective Agents
Growth Substances processed this record on August 18, 2017